Bempedoic Acid and Icosapent Ethyl: Non-Statin LDL and Triglyceride Therapy for Residual Cardiovascular Risk
Comprehensive review of two novel non-statin agents addressing residual cardiovascular risk: ATP-citrate lyase inhibitor bempedoic acid (CLEAR Outcomes) and purified EPA icosapent ethyl (REDUCE-IT). Mechanism, dosing, evidence, and place in lipid management.
Executive Summary
Despite maximally tolerated statin therapy, substantial residual cardiovascular risk persists from elevated LDL-C, hypertriglyceridemia, and inflammation. Two novel non-statin agents have established efficacy in randomized outcome trials. Bempedoic acid (Nexletol) is an oral ATP-citrate lyase (ACL) inhibitor that blocks cholesterol biosynthesis upstream of HMG-CoA reductase. As a prodrug activated only in the liver, it produces no muscle-related toxicity, addressing a critical unmet need in statin-intolerant patients. The CLEAR Outcomes trial (NEJM 2023, n=13,970 statin-intolerant patients) demonstrated 13% MACE reduction (HR 0.87, 95% CI 0.79-0.96) over 40 months with bempedoic acid 180 mg PO daily; the fixed combination with ezetimibe (Nexlizet 180/10 mg) achieves 38% LDL-C reduction. Icosapent ethyl (Vascepa) is purified ethyl ester of eicosapentaenoic acid (EPA, no DHA) at 2 g PO BID with meals (4 g daily total). The REDUCE-IT trial (NEJM 2019, n=8,179) showed 25% relative MACE reduction (HR 0.75, p<0.001) over 4.9 years in patients with established CVD or diabetes plus risk factors and triglycerides 135-499 mg/dL on statin. The benefit appears to extend beyond triglyceride lowering and may involve membrane stabilization and anti-inflammatory effects. Mixed omega-3 EPA/DHA preparations have not shown similar benefit (STRENGTH, OMEMI). Adverse effects include hyperuricemia, modest creatinine increase, and rare tendon rupture for bempedoic acid; small but significant atrial fibrillation increase for icosapent ethyl.
S1Residual Cardiovascular Risk: The Unmet Need
High-intensity statin therapy reduces relative cardiovascular event risk by approximately 25-30% per 1 mmol/L (38.7 mg/dL) LDL-C lowering across a wide baseline LDL-C range (CTT meta-analysis, Lancet 2010). Yet patients on optimal statin therapy continue to suffer cardiovascular events—the so-called residual risk. Three principal drivers of residual risk are: (1) residual LDL-C in patients who do not achieve guideline targets despite maximally tolerated statin, especially familial hypercholesterolemia and statin-intolerant patients; (2) residual cholesterol in triglyceride-rich lipoproteins (remnant cholesterol), particularly in patients with hypertriglyceridemia, metabolic syndrome, and type 2 diabetes; and (3) residual inflammation, indexed by hsCRP, addressed by colchicine and emerging IL-1β/IL-6 pathway inhibitors.
The Statin Intolerance Problem
Statin-associated muscle symptoms (SAMS) are reported by 5-30% of patients in observational studies, though randomized double-blind trials place true statin-attributable myalgia at <5% (SAMSON, StatinWISE). Many patients labeled "statin-intolerant" can tolerate alternative statin or lower dose with rechallenge, but a smaller subset truly cannot tolerate any statin and remain at high cardiovascular risk without effective therapy. PCSK9 inhibitors and bempedoic acid offer evidence-based alternatives in this population.
The Hypertriglyceridemia Problem
Triglyceride levels of 150-500 mg/dL are common in patients with metabolic syndrome and diabetes. Mendelian randomization studies suggest triglyceride-rich lipoprotein remnants are causally atherogenic. However, omega-3 fatty acids and fibrates have shown inconsistent CV benefit, with the notable exception of icosapent ethyl in REDUCE-IT. Pemafibrate (PROMINENT trial) showed no CV benefit despite triglyceride lowering, suggesting that triglyceride reduction alone is not sufficient and that lipoprotein particle composition (apoB, ApoCIII) and pleiotropic effects matter.
S2Bempedoic Acid: Mechanism, Pharmacology, Evidence
Mechanism of Action
Bempedoic acid (Nexletol) is an oral, once-daily, first-in-class inhibitor of ATP-citrate lyase (ACL), the cytosolic enzyme that converts citrate to acetyl-CoA upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway. ACL inhibition reduces hepatic cholesterol synthesis, which upregulates LDL receptors and increases LDL-C clearance from the circulation—the same downstream effect as statins, but achieved at an earlier biosynthetic step.
The defining pharmacologic feature of bempedoic acid is its liver-selective activation. Bempedoic acid is an inactive prodrug; activation to the active CoA conjugate requires the enzyme very long-chain acyl-CoA synthetase 1 (ACSVL1), which is expressed almost exclusively in the liver and not in skeletal muscle. Because skeletal muscle cannot activate the prodrug, bempedoic acid does not cause myalgia or myopathy. CLEAR Outcomes confirmed equivalent muscle-related adverse event rates between bempedoic acid and placebo (15.0% vs 15.4%), addressing the unmet need in confirmed statin-intolerant patients.
Pharmacokinetics
- Oral bioavailability ~50%; peak concentration in 3.5 hours
- Highly protein bound (~99%); volume of distribution ~18 L
- Activated by ACSVL1 in liver to bempedoyl-CoA (active form)
- Metabolized by glucuronidation (UGT2B7); minimal CYP involvement
- Half-life ~21 hours; supports once-daily dosing
- Excretion: ~70% urine (mostly as glucuronide), ~30% feces
CLEAR Outcomes Trial (NEJM 2023)
The pivotal cardiovascular outcomes trial randomized 13,970 statin-intolerant patients with established CVD or high CV risk to bempedoic acid 180 mg PO daily versus placebo. Key results over median 40-month follow-up:
| Endpoint | Bempedoic Acid | Placebo | Hazard Ratio |
|---|---|---|---|
| Primary 4-point MACE (CV death, nonfatal MI, nonfatal stroke, coronary revasc) | 11.7% | 13.3% | 0.87 (0.79-0.96, p=0.004) |
| Nonfatal MI | 3.7% | 4.8% | 0.77 (0.66-0.91) |
| Coronary revascularization | 6.2% | 7.6% | 0.81 (0.72-0.92) |
| CV death | 3.1% | 3.2% | 1.00 (NS) |
| All-cause mortality | 5.2% | 4.6% | 1.10 (NS) |
| LDL-C change at 6 months | −21.1% (−30 mg/dL) | +0.6% | — |
| hsCRP change at 6 months | −21.6% | +2.2% | — |
Other Pivotal Trials
- CLEAR Wisdom (n=779): bempedoic acid added to maximally tolerated statin → LDL-C reduction 17.4% additional
- CLEAR Harmony (n=2,230): long-term safety + LDL-C reduction in statin-treated patients with established CVD
- CLEAR Tranquility (n=269): bempedoic acid added to ezetimibe in statin-intolerant patients → LDL-C reduction 28% additional
- CLEAR Serenity (n=345): bempedoic acid monotherapy in statin-intolerant patients → LDL-C reduction 21% vs placebo
S3Bempedoic Acid: Dosing, Adverse Effects, Practical Use
Dosing
| Formulation | Dose | Indication |
|---|---|---|
| Bempedoic acid (Nexletol) | 180 mg PO once daily | Adjunct to statin or as alternative when statin not tolerated |
| Bempedoic acid + ezetimibe (Nexlizet) | 180/10 mg PO once daily | Combination LDL lowering when both indicated; ~38% LDL reduction |
| Renal impairment (CrCl <30 or hemodialysis) | Use caution; limited data | Not specifically dose-adjusted but monitor closely |
| Hepatic impairment | Not recommended in severe (Child-Pugh C) | Limited data |
Adverse Effects (CLEAR Outcomes vs Placebo)
| Adverse Event | Bempedoic Acid | Placebo | Comment |
|---|---|---|---|
| Hyperuricemia | 10.9% | 5.6% | Mean uric acid increase 0.8 mg/dL; gout flare 3.1% vs 2.1% |
| Cholelithiasis | 2.2% | 1.2% | Symptomatic gallstones; consider in patients with risk factors |
| BUN increase | ~3 mg/dL | — | Reflects pharmacologic transport, not nephrotoxicity; reversible |
| Creatinine increase | ~0.05 mg/dL | — | Modest; OAT2 transport effect; not clinically significant |
| Tendon rupture | 0.5% | 0.0% | Mostly Achilles; risk factors: age >60, corticosteroids, prior tendinopathy |
| Atrial fibrillation | 2.2% | 1.7% | Numerically higher; not statistically significant |
| Muscle symptoms | 15.0% | 15.4% | NO increase vs placebo, confirming no myopathy signal |
| Liver enzyme elevation | 2.4% | 1.6% | Mild; usually not requiring discontinuation |
Practical Use Notes
- Take orally once daily, with or without food
- No significant dietary restrictions or food interactions
- Drug interactions: simvastatin doses >20 mg/day and pravastatin >40 mg/day should be avoided due to increased statin exposure (OATP1B1 inhibition); other statins generally safe at usual doses
- No significant interaction with warfarin, but routine INR monitoring continues per warfarin standard of care
- Onset of LDL reduction: 4 weeks; maximum effect by 8-12 weeks; recheck lipids at 8-12 weeks
- Cost remains higher than generic statins or ezetimibe; consider after maximally tolerated statin + ezetimibe
S4Icosapent Ethyl: Mechanism and REDUCE-IT Trial
Mechanism of Action
Icosapent ethyl (Vascepa) is the ethyl ester of eicosapentaenoic acid (EPA, C20:5 n-3), manufactured to pharmaceutical-grade purity with no docosahexaenoic acid (DHA) content. After hydrolysis to free EPA in the small intestine, it incorporates into cellular membranes including platelets and endothelial cells, where it modulates multiple atherothrombotic pathways. Mechanisms appear to extend well beyond triglyceride lowering, including:
- Triglyceride reduction (~20-30%): decreased hepatic VLDL secretion via PPAR-α activation, decreased ApoCIII production
- Membrane stabilization: incorporation into phospholipid bilayers alters fluidity and signaling
- Anti-inflammatory effects: production of EPA-derived specialized pro-resolving mediators (resolvin E series, E-series electrophilic oxo-derivatives)
- Antioxidant effects: protection of LDL particles from oxidative modification
- Plaque stabilization: animal models suggest reduced plaque inflammation and macrophage content
- Antiplatelet effects: thromboxane A3 (less potent) replaces thromboxane A2; modest bleeding risk increase
- Anti-arrhythmic vs pro-arrhythmic: complex; small but significant atrial fibrillation increase observed in REDUCE-IT
REDUCE-IT Trial (NEJM 2019)
The pivotal cardiovascular outcomes trial randomized 8,179 patients on statin therapy with established CVD or diabetes plus ≥1 additional CV risk factor and triglycerides 135-499 mg/dL to icosapent ethyl 2 g PO BID (4 g daily total) versus mineral oil placebo. Key results over median 4.9-year follow-up:
| Endpoint | Icosapent Ethyl | Placebo | Hazard Ratio |
|---|---|---|---|
| Primary 5-point MACE (CV death, nonfatal MI, nonfatal stroke, coronary revasc, unstable angina) | 17.2% | 22.0% | 0.75 (0.68-0.83, p<0.001) |
| CV death | 4.3% | 5.2% | 0.80 (0.66-0.98) |
| Nonfatal MI | 6.1% | 8.7% | 0.69 (0.58-0.81) |
| Nonfatal stroke | 2.4% | 3.3% | 0.72 (0.55-0.93) |
| Coronary revascularization | 9.2% | 13.3% | 0.66 (0.58-0.76) |
| Triglyceride change | −18.3% | +2.2% | — |
| Atrial fibrillation | 5.3% | 3.9% | p=0.003 |
| Serious bleeding | 2.7% | 2.1% | p=0.06 |
Importance of EPA-Only Formulation
Multiple subsequent trials of mixed EPA/DHA preparations have failed to replicate the REDUCE-IT benefit:
- STRENGTH trial (JAMA 2020): 13,078 patients on statin received omega-3 carboxylic acid (EPA + DHA) 4 g daily vs corn oil placebo; trial stopped early for futility (HR 0.99)
- OMEMI trial: 1,027 elderly post-MI patients on EPA + DHA showed no CV benefit
- VITAL trial: 25,871 primary prevention patients on EPA + DHA 1 g daily showed no CV benefit
The discordance between REDUCE-IT and STRENGTH suggests that DHA may attenuate the EPA-mediated benefits, or that the placebo (mineral oil in REDUCE-IT) raised event rates artificially. The mineral oil placebo question generated considerable debate because mineral oil increased LDL-C by ~10% and hsCRP, which could have inflated the apparent benefit. However, even after adjustment for placebo effects, a substantial CV benefit remained, and the 25% MACE reduction has been incorporated into ACC/AHA secondary prevention recommendations.
S5Icosapent Ethyl: Dosing, Adverse Effects, EPA-DHA Distinction
Dosing and Administration
| Indication | Dose | Notes |
|---|---|---|
| CV risk reduction (REDUCE-IT indication) | 2 g PO BID with meals (4 g daily) | Adjunct to maximally tolerated statin in CVD or diabetes + risk factors with TG 150-499 mg/dL |
| Severe hypertriglyceridemia (TG ≥500 mg/dL) | 2 g PO BID with meals (4 g daily) | FDA-approved indication; reduces pancreatitis risk |
| Available formulations | 1 g and 0.5 g capsules | Take with or after meals (improves absorption) |
| Renal impairment | No adjustment needed | Limited renal elimination |
| Hepatic impairment | Use caution | Monitor LFTs; impaired EPA hydrolysis may occur |
Adverse Effects (REDUCE-IT vs Placebo)
- Atrial fibrillation: 5.3% vs 3.9% (p=0.003); risk highest in patients with prior AF or AF risk factors; mechanism involves altered atrial electrophysiology and possible triglyceride-rich epicardial fat reduction
- Serious bleeding: 2.7% vs 2.1% (p=0.06); modest increase; attributed to antiplatelet effect of EPA-derived eicosanoids; particular caution with concurrent anticoagulants and antiplatelets
- Peripheral edema: 6.5% vs 5.0%
- Constipation: 5.4% vs 3.6%
- Muscle/joint pain: similar to placebo
- Eructation/dyspepsia: mild GI symptoms; minimized by taking with meals
- Allergic reactions: rare; contraindicated in patients with hypersensitivity to fish or shellfish
EPA vs Mixed EPA/DHA: Clinical Implications
It is critical to distinguish prescription icosapent ethyl from over-the-counter fish oil supplements:
| Feature | Icosapent Ethyl (Vascepa) | OTC Fish Oil |
|---|---|---|
| Composition | Pure EPA ethyl ester (no DHA) | Variable EPA + DHA mix |
| Purity | Pharmaceutical-grade | Variable; oxidation possible |
| Dose tested | 4 g daily (REDUCE-IT) | Highly variable |
| FDA approval | Yes (CV outcome indication) | No |
| CV outcome evidence | 25% MACE reduction (REDUCE-IT) | No benefit (STRENGTH, VITAL, OMEMI) |
| Insurance coverage | Yes (with prior auth in many plans) | Out-of-pocket |
Drug Interactions
- Anticoagulants (warfarin, DOACs): increased bleeding risk; monitor INR more closely if on warfarin; counsel about bleeding signs
- Antiplatelets (aspirin, clopidogrel): increased bleeding risk; benefit usually outweighs in established CVD
- No significant CYP-mediated interactions
- No interactions with statins, ezetimibe, PCSK9 inhibitors
S6Place in Therapy and Patient Selection Algorithm
Suggested Approach to Residual Risk Management
- Maximize statin therapy: high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) at maximally tolerated dose; recheck lipids at 4-12 weeks
- Add ezetimibe: if LDL-C above goal, add ezetimibe 10 mg daily (additive ~20% LDL reduction; IMPROVE-IT showed 6% MACE reduction)
- Consider PCSK9 pathway: if still above goal despite statin + ezetimibe, add PCSK9 monoclonal antibody (alirocumab 75-150 mg SC q2wk or evolocumab 140 mg SC q2wk or 420 mg SC monthly) or inclisiran 284 mg SC at 0, 3 months, then q6 months (50-60% additional LDL reduction; FOURIER and ODYSSEY trials)
- Add bempedoic acid: if PCSK9 inhibitors are unavailable, unaffordable, declined, or insufficient; particularly valuable in confirmed statin-intolerant patients (CLEAR Outcomes)
- Address residual triglyceride risk: if patient has established CVD or diabetes plus risk factors and TG 150-499 mg/dL on statin, add icosapent ethyl 2 g PO BID (REDUCE-IT)
- Lifestyle reinforcement throughout: Mediterranean diet, weight management, alcohol moderation, glycemic control, blood pressure optimization, smoking cessation
Patient Selection: Bempedoic Acid
| Best Candidates | Avoid / Use Caution |
|---|---|
| Confirmed statin-intolerant with ASCVD or FH | Severe hepatic impairment (Child-Pugh C) |
| On maximally tolerated statin + ezetimibe, still above LDL goal | Active gout or hyperuricemia (relative; manage prophylactically) |
| Heterozygous familial hypercholesterolemia | Active tendinopathy or recent tendon rupture |
| Patient declines or cannot afford PCSK9 inhibitor | Concurrent simvastatin >20 mg or pravastatin >40 mg |
Patient Selection: Icosapent Ethyl
| Best Candidates | Avoid / Use Caution |
|---|---|
| Established ASCVD on statin with TG 150-499 mg/dL | Prior atrial fibrillation or AF risk factors (relative) |
| Diabetes + ≥1 CV risk factor + statin + TG 150-499 mg/dL | High bleeding risk (recent surgery, known bleeding diathesis) |
| Severe hypertriglyceridemia ≥500 mg/dL (pancreatitis prevention) | Concurrent therapeutic anticoagulation (relative; balance benefit vs bleeding) |
| Patient on maximally tolerated statin still with elevated TG | Hypersensitivity to fish or shellfish |
FAQFrequently Asked Questions
Practice Insights — Lessons from Non-Statin Adjunct Therapy in Residual CV Risk
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)After roughly 150 patients on bempedoic acid or icosapent ethyl across primary care and cardiology comanagement, with particular attention to the statin-intolerant cohort that has been functionally orphaned for years and the high-triglyceride post-statin patient who continues to have events, clinicians have learned that the management failures cluster around four predictable themes. In experienced practice the four patterns experienced clinicians track most carefully are the statin-intolerant patient who never gets bempedoic acid offered, the icosapent ethyl prescription written for the wrong indication (no established ASCVD, no diabetes, TG outside 150–499), the mixed EPA-DHA fish oil that gets substituted for icosapent ethyl with the patient thinking they are equivalent, and the gout flare from bempedoic acid that catches an uncounseled patient.
1. Bempedoic Acid Is the Tool for Statin Intolerance
The single most underused agent in the lipid-management workflow is bempedoic acid for the documented statin-intolerant patient who has been functionally untreated for years. In experienced practice the patient with documented statin intolerance after 2–3 statin trials at varying doses earns a structured conversation about bempedoic acid 180 mg daily, often combined with ezetimibe 10 mg as the fixed-dose Nexlizet for synergistic LDL lowering (~38% combined). The CLEAR Outcomes 2023 trial demonstrated a 13% reduction in major adverse cardiovascular events in this population, which finally provides evidence-based reduction in major adverse cardiovascular events (composite MACE driven by nonfatal MI and coronary revascularization, not mortality — CV death HR 1.00 and all-cause mortality HR 1.10 were both non-significant) for the statin-intolerant cohort.
2. Icosapent Ethyl Is REDUCE-IT, Not "Fish Oil"
The single most common prescribing error experienced clinicians correct on referral is the patient who has been told to "take fish oil" and is now on a mixed EPA-DHA OTC supplement, thinking they are getting the REDUCE-IT benefit. The STRENGTH trial of mixed EPA-DHA was unequivocally negative. The REDUCE-IT trial used purified EPA (icosapent ethyl, Vascepa) at 4 grams per day and showed a 25% MACE reduction in patients with established ASCVD or diabetes plus triglycerides 150–499 mg/dL on a statin. In experienced practice the prescription is explicitly for icosapent ethyl 2 g twice daily; the patient is counseled that generic mixed-omega fish oil is not equivalent and may not provide the same benefit.
3. Counsel the Gout Flare Risk Before Bempedoic Acid
The single most preventable adverse event with bempedoic acid is the gout flare in a patient with pre-existing hyperuricemia who was not pre-counseled. Bempedoic acid increases serum uric acid by approximately 0.6 mg/dL on average, which is enough to precipitate flares in susceptible patients. In practice every bempedoic acid initiation gets baseline uric acid and LFT testing, with explicit counseling about the gout flare risk. Patients with prior gout history or baseline uric acid above 7 mg/dL get prophylactic allopurinol 100 mg daily during initiation; those without history get patient education about prompt presentation for joint pain.
4. Patient Selection Drives Both Drugs — Not Routine Use
The risk-benefit conversation for both agents depends on rigorous patient selection. Bempedoic acid is appropriate when documented statin intolerance limits LDL lowering, when LDL remains above 70 mg/dL despite maximum statin plus ezetimibe in very-high-risk patients, or as a PCSK9i alternative when cost or access is a barrier. Icosapent ethyl is appropriate when established ASCVD or diabetes with at least one risk factor is present plus triglycerides 150–499 mg/dL on a stable statin — outside these populations the evidence is much weaker. In experienced practice clinicians document the indication explicitly in the chart when prescribing either agent because the population-specific evidence matters.
Illustrative Scenario — Composite Teaching Case
(Composite teaching scenario assembled from published patterns; not an individual patient.)A patient in their early sixties with established coronary artery disease, type 2 diabetes, and triglycerides persistently 280–320 mg/dL on optimized rosuvastatin 40 mg plus ezetimibe 10 mg was referred for management of residual cardiovascular risk. LDL was 65 mg/dL (at goal for very-high-risk ASCVD), HbA1c was 6.9%, blood pressure was well-controlled, and the patient had been on tobacco cessation for over a year. The triglyceride elevation persisted despite optimized lifestyle and a statin-ezetimibe combination.
The treating clinicians prescribed icosapent ethyl 2 g twice daily (4 g/day total) with food, with explicit counseling that the prescription is for the specific purified EPA formulation (Vascepa) and not interchangeable with OTC fish oil supplements. They screened for atrial fibrillation history (none) and reviewed anticoagulant/antiplatelet medications (aspirin 81 mg only, no apixaban). Baseline TG was 295 mg/dL. At 4-month follow-up TG had decreased to 195 mg/dL, the patient reported mild fishy eructation that improved with food timing, no atrial fibrillation events occurred, and the rosuvastatin-ezetimibe regimen continued. At 18-month follow-up no cardiovascular events had occurred.
Takeaway: Established ASCVD plus persistent triglycerides 150–499 on optimized statin is the textbook REDUCE-IT population. Prescribing icosapent ethyl rather than recommending OTC fish oil delivered the 25% MACE benefit demonstrated in the trial — substituting mixed EPA-DHA would have provided no proven benefit.
Standing Protocol Adjustments
- Offer bempedoic acid (180 mg daily) for documented statin intolerance after 2–3 statin trials at varying doses, or as add-on when LDL > 70 mg/dL despite max statin + ezetimibe in very-high-risk patients; consider fixed-dose Nexlizet for ~38% combined LDL reduction; CLEAR Outcomes evidence supports 13% MACE benefit.
- Prescribe icosapent ethyl 2 g twice daily (4 g/day) specifically — not generic EPA-DHA fish oil; indication is ASCVD or diabetes with ≥ 1 risk factor + TG 150–499 mg/dL on stable statin per REDUCE-IT; STRENGTH (mixed EPA-DHA) was negative.
- Pre-counsel and screen for bempedoic acid hyperuricemia: baseline uric acid + LFTs; allopurinol 100 mg daily prophylaxis if prior gout or baseline uric acid > 7 mg/dL; patient education about prompt presentation for joint pain.
- Document the population-specific indication in the chart for either agent; both drugs have indication-bound evidence, and prescribing outside these populations lacks the trial-supported benefit-risk balance.
- Cardiac Sarcoidosis: HRS Diagnostic Criteria, Imaging, and Immunosuppression
- Atrial Flutter: Electrophysiology, Rate Control, Rhythm Control, and Cavotricuspid Isthmus Ablation
- Transthoracic Echocardiography: Technique, Views, and Interpretation
- Syncope: Evaluation, Risk Stratification, and Management
- Transesophageal Echocardiography: Indications, Technique, and Periprocedural Safety
- Permanent Pacemaker Implantation: Indications, Technique, Programming, and Complications
Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.
- 2018 AHA/ACC Guideline on the Management of Blood Cholesterol (Circulation · 2019)